De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy.
Enhanced lipid biosynthesis is a characteristic feature of cancer. Deregulated lipogenesis plays an important role in tumour cell survival. These observations suggest that enzymes in the lipid synthesis pathway would be rational therapeutic targets for cancer. To this end, we review the enzymes in de novo fatty-acid synthesis and related pathways.
Mashima
T
T
Division of Molecular Biotherapy, Cancer Chemotherapy Centre, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan. tmashima@jfcr.or.jp
Seimiya
H
H
Tsuruo
T
T
D001275:ATP Citrate (pro-S)-Lyase / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003066:Coenzyme A Ligases / Q000378:metabolism; D015195:Drug Design; D054890:Fatty Acid Synthase, Type I / Q000235:genetics / Q000378:metabolism; D005227:Fatty Acids / Q000096:biosynthesis*; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology
D000970:Antineoplastic Agents; D005227:Fatty Acids; C518729:FASN protein, human; D054890:Fatty Acid Synthase, Type I; D001275:ATP Citrate (pro-S)-Lyase; D003066:Coenzyme A Ligases